Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains

References

1. Anon. 2001; Acute flaccid paralysis associated with circulating vaccine-derived poliovirus – Philippines, 2001. Morb Mortal Wkly Rep 50:874–875
   [Google Scholar]
2. Cabasso V. J., Jervis G. A., Moyer A. W., Roca-Garcia M., Orsi E. V., Cox H. R. 1959; Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. In Live Poliovirus Vaccines . First International Conference on Live Poliovirus Vaccines pp  102–134 Washington, DC: Pan American Sanitary Bureau;
   [Google Scholar]
3. Centers for Disease Control & Prevention; 2001; Circulation of a type 2 vaccine-derived poliovirus – Egypt, 1982–1993. JAMA 285:1148–1149
   [Google Scholar]
4. Doi Y., Abe S., Yamamoto H. 8 other authors 2001; Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol 105:163–169
   [Google Scholar]
5. Dowdle W. R., Featherstone D. A., Birmingham M. E., Hull H. F., Aylward R. B. 1999; Poliomyelitis eradication. Virus Res 62:185–192
   [Google Scholar]
6. Dowdle W. R., Gary H. E., Sanders R., van Loon A. M. 2002; Can post-eradication laboratory containment of wild polioviruses be achieved?. Bull World Health Organ 80:311–316
   [Google Scholar]
7. Ferguson M., Wood D. J., Minor P. D. 1993; Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 74:685–690
   [Google Scholar]
8. Hovi T. 2001; Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 19:2268–2272
   [Google Scholar]
9. Kersten G., Hazendonk T., Beuvery C. 1999; Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17:2059–2066
   [Google Scholar]
10. Kew O., Morris-Glasgow V., Landaverde M. 21 other authors 2002; Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 14:14
    [Google Scholar]
11. Koprowski H. 1958; Vaccination with modified active viruses. In Poliomyelitis . Papers and Discussion Presented at the Fourth International Poliomyelitis Conference pp  112–123 Philadelphia: Lippincott;
    [Google Scholar]
12. Lu H. H., Yang C. F., Murdin A. D., Klein M. H., Harber J. J., Kew O. M., Wimmer E. 1994; Mouse neurovirulence determinants of poliovirus type 1 strain LS – a map to the coding regions of capsid protein VP1 and proteinase 2Apro. J Virol 68:7507–7515
    [Google Scholar]
13. Martin J., Minor P. D. 2002; Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 76:5339–5349
    [Google Scholar]
14. McGoldrick A., Macadam A. J., Dunn G., Rowe A., Burlison J., Minor P. D., Meredith J., Evans D. J., Almond J. W. 1995; Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 69:7601–7605
    [Google Scholar]
15. Melnick J. L. 1994; Live attenuated poliovirus vaccines. In Vaccines pp  155–204 Edited by Plotkin S. A., Mortimer E. A. Jr Philadelphia: W. B. Saunders;
    [Google Scholar]
16. Minor P. D. 1980; Comparative biochemical studies of type 3 poliovirus. J Virol 34:73–84
    [Google Scholar]
17. Minor P. D. 1990; Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 161:121–154
    [Google Scholar]
18. Minor P. D., John A., Ferguson M., Icenogle J. P. 1986; Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol 67:693–706
    [Google Scholar]
19. Murdin A. D., Barreto L., Plotkin S. 1996; Inactivated poliovirus vaccine: past and present experience. Vaccine 14:735–746
    [Google Scholar]
20. Murph J. R., Grose C., McAndrew P., Mickiewicz C., Mento S., Cano F., Radick L., Ritchey M., Stout M. G. 1988; Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 7:760–765
    [Google Scholar]
21. Salk J., Drucker J. A., Malvy D. 1994; Noninfectious poliovirus vaccine. In Vaccines pp  205–228 Edited by Plotkin S. A, Mortimer E. A. Jr Philadelphia: W. B. Saunders;
    [Google Scholar]
22. Singer C., Knauert F., Bushar G., Klutch M., Lundquist R., Quinnan G. V. Jr 1989; Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand 17:137–150
    [Google Scholar]
23. Strebel P. M., Sutter R. W., Cochi S. L., Biellik R. J., Brink E. W., Kew O. M., Pallansch M. A., Orenstein W. A., Hinman A. R. 1992; Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14:568–579
    [Google Scholar]
24. Taffs R. E., Chernokhvostova Y. V., Dragunsky E. M., Nomura T., Hioki K., Beuvery E. C., Fitzgerald E. A., Levenbook I. S., Asher D. M. 1997; Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. J Infect Dis 175:441–444
    [Google Scholar]
25. Toyoda H., Kohara M., Kataoka Y., Suganuma T., Omata T., Imura N., Nomoto A. 1984; Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J Mol Biol 174:561–585
    [Google Scholar]
26. Twomey T., Newman J., Burrage T., Piatti P., Lubroth J., Brown F. 1995; Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13:1603–1610
    [Google Scholar]
27. World Health Organization 1997 Manual for the Virological Investigation of Poliomyelitis Geneva: World Health Organization;
    [Google Scholar]